Hinge Health: CFO James Budge Sells 44,589 Shares; Stock Reaction, Buyback and Analyst Views
Hinge Health Inc. (NYSE: HNGE) Chief Financial Officer James Budge sold 44,589 shares on Tuesday, November 25, according to a Securities and Exchange Commission filing. The shares were disposed of at an average price of $47.47, for proceeds totaling $2,116,639.83. After the transaction, Budge owned 479,878 shares—an 8.50% reduction in his stake—valued at roughly $22.78 million at the reported price. The sale is disclosed in the company’s Form 4 filing with the SEC (see filing).
Intraday Trading and Range
Shares of Hinge Health traded higher mid-day on Tuesday, rising $1.26 to $48.27. Volume for the session was about 1.10 million shares versus the stock’s average volume of roughly 2.43 million. The company’s 50-day simple moving average sits near $49.26, with a 12-month range between $33.42 and $62.18. (More trading and insider-trade context is available from MarketBeat: HNGE insider trades.)
Earnings, Guidance and Share-Repurchase
Hinge Health reported quarterly results on November 4, posting adjusted earnings that beat consensus estimates. The company reported ($0.02) EPS for the quarter versus a consensus estimate of ($0.20), and revenue of $154.21 million compared with analysts’ estimates of $142.44 million—representing year-over-year revenue growth of 53.3%. The original MarketBeat text notes the company’s FY 2025 and Q4 2025 guidance as: “Hinge Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS.”
On November 12, Hinge Health’s board authorized a stock repurchase program of up to $250.0 million, which the company says could result in buying as much as 7.2% of outstanding shares through open-market purchases. Management and boards often deploy buybacks to return capital or signal confidence in a company’s valuation.
Wall Street Snapshot
Several firms have recently updated their coverage. Bank of America raised its price objective from $42.00 to $64.00 and reiterated a “buy” rating. Stifel Nicolaus lifted its target to $66.00 with a “buy” rating. Morgan Stanley increased its objective to $67.00 and rates the stock “overweight.” JMP Securities moved its target to $65.00 with a “market outperform” rating, and Canaccord Genuity raised its target to $65.00 with a “buy”. MarketBeat’s aggregation shows one Strong Buy, fifteen Buys, two Holds and one Sell, with an average target near $59.93.
Institutional Activity
Several institutional investors added new positions in the third quarter, according to the original article: Jacobs Levy Equity Management purchased a new stake worth about $743,000; Dark Forest Capital Management acquired roughly $290,000; Voleon Capital Management added approximately $5.99 million; Verition Fund Management bought about $238,000; and Scientech Research opened a position around $328,000.
About Hinge Health
Hinge Health’s stated vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. The company leverages software, including AI, to largely automate care for joint and muscle health, aiming to improve member outcomes and reduce costs for clients. (More corporate detail is available via MarketBeat’s company report: Get Free Report.)
